CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Millions, unless otherwise specified	Mar. 31, 2013		Dec. 31, 2012
Assets
Cash and cash equivalents	$ 2,134		$ 10,389
Short-term investments	33,212		22,319
Accounts receivable, less allowance for doubtful accounts	12,735		12,378
Inventories	7,035		7,063
Taxes and other current assets	9,647		9,266
Total current assets	64,763		61,415
Long-term investments	15,392		14,149
Property, plant and equipment, less accumulated depreciation	13,950		14,461
Goodwill	43,752		44,672
Identifiable intangible assets, less accumulated amortization	44,109	[1]	46,013	[1]
Taxes and other noncurrent assets	5,432		5,088
Total assets	187,398		185,798
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt	8,896	[2],[3]	6,424	[2],[3]
Accounts payable	3,279		4,264
Dividends payable	5		1,734
Income taxes payable	1,158		1,010
Accrued compensation and related items	1,684		2,046
Other current liabilities	12,521		13,141
Total current liabilities	27,543		28,619
Long-term debt	31,481	[2],[4],[5]	31,036	[2],[4],[5]
Pension benefit obligations	7,733		7,830
Postretirement benefit obligations	3,470		3,493
Noncurrent deferred tax liabilities	22,445		21,593
Other taxes payable	6,761		6,610
Other noncurrent liabilities	5,138		4,939
Total liabilities	104,571		104,120
Commitments and Contingencies
Preferred stock	38		39
Common stock	450		448
Additional paid-in capital	75,778		72,608
Employee benefit trusts	(1)		(1)
Treasury stock	(44,832)		(40,121)
Retained earnings	56,972		54,240
Accumulated other comprehensive loss	(6,155)		(5,953)
Total Pfizer Inc. shareholders' equity	82,250		81,260
Equity attributable to noncontrolling interests	577		418
Total equity	82,827		81,678
Total liabilities and equity	$ 187,398		$ 185,798

[1] The decrease is primarily related to amortization, an asset impairment charge and the transfer of certain product rights to our equity-method investment in China. For additional information about the asset impairment charge, see Note 4. Other Deductions—Net. For additional information about the transfer of certain product rights, see Note 2D. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Equity-Method Investment.

[2] Some carrying amounts may include adjustments for discount or premium amortization or for the effect of interest rate swaps designated as hedges.

[3] The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities at cost and short-term borrowings not measured at fair value on a recurring basis were not significant as of March 31, 2013 or December 31, 2012. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our private equity securities at cost are based on Level 3 inputs, using a market approach.

[4] The fair value of our long-term debt (not including the current portion of long-term debt) is $37.8 billion as of March 31, 2013 and $37.5 billion as of December 31, 2012. The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach.

[5] Includes foreign currency debt with fair values of $735 million as of March 31, 2013 and $809 million as of December 31, 2012, which are used as hedging instruments.